Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Haeseong Park, Michael Iglesia, Katrina Sophia Pedersen, Patrick Grierson, Zishuo Ian Hu, Rama Suresh, Benjamin R. Tan, Nikolaos Trikalinos, Olivia Aranha, Katherine Navo, David G. DeNardo, Matthew A. Ciorba, Katlyn Kraft, Feng Gao, Elizabeth Martinez, Reinhard von Roemeling, Felix Geissler, Kian-Huat Lim
Institutions: Washington University in St. Louis, Curis (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286295731